cp-690550 tofacitinib maleate

Tofacitinib maleate, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib maleate modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib maleate inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively.

CP-465022 Maleate is a potent, selective, noncompetitive AMPA receptor antagonist with anticonvulsant activity. It effectively counters the Kainate-induced response in rat cortical neurons, exhibiting an IC 50 of 25 nM. As such, CP-465022 Maleate presents a valuable instrument for studying the involvement of AMPA receptors in various physiological and pathophysiological processes [1] [2].

Quoromycin is a novel antivirulence agent against Vibrio vulnificus, inhibiting the quorum-sensing signaling pathway by controlling the DNA-binding affinity of SmcR and thus effectively alleviating the virulence of V. vulnificus in vitro and in vivo.